Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023)

Protara Therapeutics' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2023.

• In Q4 2023, Non-Current Deferred Tax Liability rose 7240.91% year-over-year to $1.6 million; the TTM figure through Dec 2023 stood at $1.6 million (up 7240.91% YoY), while the FY2023 annual figure was $1.6 million, up 7240.91% from the prior year.
• Non-Current Deferred Tax Liability was $1.6 million for Q4 2023 at Protara Therapeutics, up from -$22000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.6 million in Q4 2023 to a low of -$22000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $684400.0 across 5 years, with a median of $322000.0 in 2020.
• The sharpest annual moves came in 2020 and 2022: Non-Current Deferred Tax Liability soared 16000.0% in 2020, then sank 101.42% in 2022.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2000.0 in 2019, then jumped by 16000.0% to $322000.0 in 2020, then jumped by 381.06% to $1.5 million in 2021, then tumbled by 101.42% to -$22000.0 in 2022, then surged by 7240.91% to $1.6 million in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $1.6 million (Q4 2023), -$22000.0 (Q4 2022), and $1.5 million (Q4 2021), per Business Quant data.